| Literature DB >> 19142570 |
Malcolm Steiger1, W Jost, F Grandas, G Van Camp.
Abstract
UNLABELLED: A literature review was conducted to assess risk of cardiac valve regurgitation (CVR) associated with use of ergot-derived and non-ergot dopamine agonists (DAs) in patients with Parkinson's disease (PD). INCLUSION CRITERIA: case-control/observational studies of >10 patients with PD treated with DAs, including a control group and assessment of incidence/risk of CVR. Of the 166 publications identified, 14 met all inclusion criteria and included 1,750 patients. In 11 of the studies, a significant increase in CVR frequency of any severity (at the aortic, mitral or tricuspid valve) in the ergot group vs. the non-ergot or control group was described. No study reported increased risk of CVR for non-ergot DAs, compared with controls. In the studies identified in the literature, the use of ergot-derived DAs (pergolide and cabergoline) in patients with PD was associated with increased risk of CVR. Increased risk of CVR was not associated with the use of non-ergot DAs.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19142570 DOI： 10.1007/s00702-008-0179-4
Source DB: PubMed Journal: J Neural Transm (Vienna) ISSN： 0300-9564 Impact factor: 3.575